101
|
Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms. Clin Sci (Lond) 2017; 131:635-651. [DOI: 10.1042/cs20160380] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2016] [Revised: 01/04/2017] [Accepted: 01/16/2017] [Indexed: 01/08/2023]
Abstract
Cerebral small vessel diseases (SVDs) are a leading cause of age and hypertension-related stroke and dementia. The salient features of SVDs visible on conventional brain magnetic resonance images include white matter hyperintensities (WMHs) on T2-weighted images, small infarcts, macrohemorrhages, dilated perivascular spaces, microbleeds and brain atrophy. Among these, WMHs are the most common and often the earliest brain tissue changes. Moreover, over the past two decades, large population- and patient-based studies have established the clinical importance of WMHs, notably with respect to cognitive and motor disturbances. Here, we seek to provide a new and critical look at the pathogenesis of SVD-associated white matter (WM) changes. We first review our current knowledge of WM biology in the healthy brain, and then consider the main clinical and pathological features of WM changes in SVDs. The most widely held view is that SVD-associated WM lesions are caused by chronic hypoperfusion, impaired cerebrovascular reactivity (CVR) or blood–brain barrier (BBB) leakage. Here, we assess the arguments for and against each of these mechanisms based on population, patient and experimental model studies, and further discuss other potential mechanisms. Specifically, building on two recent seminal studies that have uncovered an anatomical and functional relationship between oligodendrocyte progenitor cells and blood vessels, we elaborate on how small vessel changes might compromise myelin remodelling and cause WM degeneration. Finally, we propose new directions for future studies on this hot research topic.
Collapse
|
102
|
Snaidero N, Simons M. The logistics of myelin biogenesis in the central nervous system. Glia 2017; 65:1021-1031. [DOI: 10.1002/glia.23116] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 12/06/2016] [Accepted: 12/12/2016] [Indexed: 01/28/2023]
Affiliation(s)
- Nicolas Snaidero
- Institute of Neuronal Cell Biology, Technical University Munich; Munich 80805 Germany
| | - Mikael Simons
- Institute of Neuronal Cell Biology, Technical University Munich; Munich 80805 Germany
- German Center for Neurodegenerative Disease (DZNE); Munich 6250 Germany
- Cellular Neuroscience; Max Planck Institute of Experimental Medicine; Göttingen 37075 Germany
- Munich Cluster for Systems Neurology (SyNergy); Munich 81377 Germany
| |
Collapse
|
103
|
Weil MT, Ruhwedel T, Möbius W, Simons M. Intracerebral Injections and Ultrastructural Analysis of High-Pressure Frozen Brain Tissue. ACTA ACUST UNITED AC 2017; 78:2.27.1-2.27.18. [PMID: 28046202 DOI: 10.1002/cpns.22] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Intracerebral injections are an invasive method to bypass the blood brain barrier and are widely used to study molecular and cellular mechanisms of the central nervous system. The administered substances are injected directly at the site of interest, executing their effect locally. By combining injections in the rat brain with state-of-the-art electron microscopy, subtle changes in ultrastructure of the nervous tissue can be detected prior to overt damage or disease. The protocol presented here involves stereotactic injection into the corpus callosum of Lewis rats and the cryopreparation of freshly dissected tissue for electron microscopy. The localization of the injection site in tissue sections during the sample preparation for transmission electron microscopy is explained and possible artifacts of the method are indicated. With the help of this powerful combination of injections and electron microscopy, subtle effects of the applied substances on the biology of neural cells can be identified and monitored over time. © 2017 by John Wiley & Sons, Inc.
Collapse
Affiliation(s)
- Marie-Theres Weil
- Department of Cellular Neuroscience, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.,Department of Neurogenetics, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.,Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Torben Ruhwedel
- Department of Neurogenetics, Max-Planck Institute for Experimental Medicine, Göttingen, Germany
| | - Wiebke Möbius
- Department of Neurogenetics, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.,Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Mikael Simons
- Department of Cellular Neuroscience, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.,Institute of Neuronal Cell Biology, The Technical University of Munich, Munich, Germany.,German Center for Neurodegenerative Disease (DZNE), Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| |
Collapse
|
104
|
Romanelli E, Merkler D, Mezydlo A, Weil MT, Weber MS, Nikić I, Potz S, Meinl E, Matznick FEH, Kreutzfeldt M, Ghanem A, Conzelmann KK, Metz I, Brück W, Routh M, Simons M, Bishop D, Misgeld T, Kerschensteiner M. Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model. Nat Commun 2016; 7:13275. [PMID: 27848954 PMCID: PMC5116090 DOI: 10.1038/ncomms13275] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 09/19/2016] [Indexed: 12/14/2022] Open
Abstract
Oligodendrocyte damage is a central event in the pathogenesis of the common neuroinflammatory condition, multiple sclerosis (MS). Where and how oligodendrocyte damage is initiated in MS is not completely understood. Here, we use a combination of light and electron microscopy techniques to provide a dynamic and highly resolved view of oligodendrocyte damage in neuroinflammatory lesions. We show that both in MS and in its animal model structural damage is initiated at the myelin sheaths and only later spreads to the oligodendrocyte cell body. Early myelin damage itself is characterized by the formation of local myelin out-foldings-'myelinosomes'-, which are surrounded by phagocyte processes and promoted in their formation by anti-myelin antibodies and complement. The presence of myelinosomes in actively demyelinating MS lesions suggests that oligodendrocyte damage follows a similar pattern in the human disease, where targeting demyelination by therapeutic interventions remains a major open challenge.
Collapse
Affiliation(s)
- Elisa Romanelli
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Doron Merkler
- Department of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland
- Division of Clinical Pathology, Geneva University Hospital, 1211 Geneva, Switzerland
| | - Aleksandra Mezydlo
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Marie-Theres Weil
- Max-Planck Institute of Experimental Medicine, 37075 Göttingen, Germany
- Department of Neurology, Georg-August University Göttingen, 37075 Göttingen, Germany
| | - Martin S. Weber
- Department of Neurology, Georg-August University Göttingen, 37075 Göttingen, Germany
- Institute of Neuropathology, Georg-August University Göttingen, 37075 Göttingen, Germany
| | - Ivana Nikić
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Stephanie Potz
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Edgar Meinl
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Florian E. H. Matznick
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Mario Kreutzfeldt
- Department of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland
| | - Alexander Ghanem
- Max von Pettenkofer-Institute and Gene Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Karl-Klaus Conzelmann
- Max von Pettenkofer-Institute and Gene Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
| | - Imke Metz
- Institute of Neuropathology, Georg-August University Göttingen, 37075 Göttingen, Germany
| | - Wolfgang Brück
- Institute of Neuropathology, Georg-August University Göttingen, 37075 Göttingen, Germany
| | - Matthew Routh
- Department of Physiology and Health Science, Ball State University, Muncie, Indiana 47306, USA
| | - Mikael Simons
- Max-Planck Institute of Experimental Medicine, 37075 Göttingen, Germany
- Department of Neurology, Georg-August University Göttingen, 37075 Göttingen, Germany
- German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany
- Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany
- Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany
| | - Derron Bishop
- Department of Cellular and Integrative Physiology and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
| | - Thomas Misgeld
- German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany
- Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany
- Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany
- Center of Integrated Protein Sciences (CIPS), 81377 Munich, Germany
| | - Martin Kerschensteiner
- Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 81377 Munich, Germany
- Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany
| |
Collapse
|